{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T05:15:30Z","timestamp":1721625330556},"reference-count":67,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["heartlungcirc.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.hlc.2016.12.005","type":"journal-article","created":{"date-parts":[[2017,1,23]],"date-time":"2017-01-23T19:15:22Z","timestamp":1485198922000},"page":"786-798","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges"],"prefix":"10.1016","volume":"26","author":[{"given":"Hashrul","family":"Rashid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian T.","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Nasis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2016.12.005_bib0005","unstructured":"World Health Organisation: Cardiovascular diseases (CVDs) 2015. http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/.(accessed January 1, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0010","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/CIRCULATIONAHA.111.073684","article-title":"Lipids and lipoproteins and risk of different vascular events in the MRC\/BHF Heart Protection Study","volume":"125","author":"Parish","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2016.12.005_bib0015","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2016.12.005_bib0020","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2016.12.005_bib0025","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural Mechansim for Statin Inhibition of HMG-CoA Reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science (80-)"},{"key":"10.1016\/j.hlc.2016.12.005_bib0030","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of Coronary Heart Disease With Pravastatin in Men With","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2016.12.005_bib0035","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2016.12.005_bib0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","article-title":"Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote","volume":"7979","author":"Zhao","year":"2006","journal-title":"Am J Hum Genet Dallas Am J Hum Genet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0050","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1194\/jlr.M003566","article-title":"Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters","volume":"51","author":"Dong","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.hlc.2016.12.005_bib0060","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of Proprotein Convertase Subtilisin\/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.hlc.2016.12.005_bib0065","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/embor.2011.205","article-title":"Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH","volume":"12","author":"Surdo","year":"2011","journal-title":"EMBO Rep"},{"key":"10.1016\/j.hlc.2016.12.005_bib0070","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0075","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1093\/eurheartj\/ehv174","article-title":"PCSK9 (Proprotein convertase subtilisin\/kexin type 9) inhibitors: past, present, and the future","volume":"36","author":"Shimada","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2016.12.005_bib0080","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.hlc.2016.12.005_bib0085","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.hlc.2016.12.005_bib0090","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.jacc.2012.08.986","article-title":"Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins","volume":"60","author":"Dias","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0095","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","article-title":"Effect of a monoclonal antibody to PCSK9 on LDL cholesterol","volume":"366","author":"Stein","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2016.12.005_bib0100","doi-asserted-by":"crossref","unstructured":"Keating GM. Evolocumab: A Review in Hyperlipidemia. Am J Cardiovasc Drugs 2015.","DOI":"10.1007\/s40256-015-0153-0"},{"key":"10.1016\/j.hlc.2016.12.005_bib0105","unstructured":"FDA approves Repatha to treat certain patients with high cholesterol n.d. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm460082.htm.(accessed September 9, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0110","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study","volume":"380","author":"Koren","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0115","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","article-title":"Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibiti","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.hlc.2016.12.005_bib0120","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0125","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jama.2015.11372","article-title":"Alirocumab (Praluent) to Lower LDL-Cholesterol","volume":"314","author":"Guidelines","year":"2015","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.hlc.2016.12.005_bib0130","unstructured":"FDA approves Praluent to treat certain patients with high cholesterol n.d. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm455883.htm.(accessed September 9, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0135","unstructured":"Prescription medicines: registration of new chemical entities in Australia 2016. https:\/\/www.tga.gov.au\/prescription-medicines-registration-new-chemical-entities-australia.(accessed October 17, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0140","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","article-title":"Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy","volume":"59","author":"McKenney","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0145","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","article-title":"Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia","volume":"367","author":"Roth","year":"2012","journal-title":"N Engl J Med 2012"},{"key":"10.1016\/j.hlc.2016.12.005_bib0150","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","article-title":"Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin\/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia","volume":"115","author":"Ballantyne","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0155","unstructured":"The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE 1) n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975376.(accessed January 14, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0160","unstructured":"The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2) n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01975389?term=SPIRE-2&rank=1 (accessed January 14, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","article-title":"Prevalence and treatment of familial hypercholesterolaemia in Australian communities","volume":"185","author":"Watts","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0170","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0175","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(14)61374-X","article-title":"Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): A randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10557-014-6523-z","article-title":"Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: Design and rationale of the ODYSSEY FH studies","volume":"28","author":"Kastelein","year":"2014","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hlc.2016.12.005_bib0185","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0190","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0195","doi-asserted-by":"crossref","first-page":"A1370","DOI":"10.1016\/S0735-1097(15)61370-5","article-title":"Efficacy and safety of different dosing regimens of Alirocumab versus placebo in patients with hypercholesterolaemia: The ODYSSEY Choice II Study","volume":"65","author":"Stroes","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0200","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: The MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ijcard.2014.06.049","article-title":"Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial","volume":"176","author":"Roth","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0210","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia","volume":"311","author":"Robinson","year":"2014","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.hlc.2016.12.005_bib0215","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.hlc.2016.12.005_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.hlc.2016.12.005_bib0225","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2016.12.005_bib0230","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as Add-on To Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.hlc.2016.12.005_bib0235","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.atherosclerosis.2015.11.010","article-title":"Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial","volume":"244","author":"Farnier","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hlc.2016.12.005_bib0240","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 Monotherapy for Hypercholesterolemia","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.hlc.2016.12.005_bib0245","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.hlc.2016.12.005_bib0250","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hlc.2016.12.005_bib0255","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"1\u201312","author":"Lipinski","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hlc.2016.12.005_bib0260","unstructured":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Clinicaltrials.gov 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01764633.(accessed January 15, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0265","unstructured":"ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab. Clinicaltrials.gov 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01663402 (accessed January 15, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0270","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind a barrier","volume":"24","author":"Bj\u00f6rkhem","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0275","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","article-title":"Lipid lowering with PCSK9 inhibitors","volume":"11","author":"Dadu","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hlc.2016.12.005_bib0280","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","article-title":"Statin-associated adverse cognitive effects: survey results from 171 patients","volume":"29","author":"Evans","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.hlc.2016.12.005_bib0285","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00002018-200932080-00004","article-title":"Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study","volume":"32","author":"Golomb","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.hlc.2016.12.005_bib0290","unstructured":"FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs n.d."},{"key":"10.1016\/j.hlc.2016.12.005_bib0295","first-page":"CD007514","article-title":"Statins for the treatment of dementia","author":"McGuinness","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.hlc.2016.12.005_bib0300","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2016.12.005_bib0305","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2013.07.013","article-title":"Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects","volume":"88","author":"Swiger","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.hlc.2016.12.005_bib0310","unstructured":"Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS). Clinicaltrials.gov 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02207634.(accessed January 15, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0315","unstructured":"GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound (GLAGOV). Clinicaltrials.gov 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01813422.(accessed January 15, 2016)."},{"key":"10.1016\/j.hlc.2016.12.005_bib0320","unstructured":"Institute for Clinical and Economic Review. PCSK9 Inhibitors for Treatment of High Cholesterol: Effectiveness, Value, and Value-Based Price Benchmarks Draft Report 2015:1-116. https:\/\/icer-review.org\/wp-content\/uploads\/2016\/01\/Final-Report-for-Posting-11-24-15-1.pdf."},{"key":"10.1016\/j.hlc.2016.12.005_bib0325","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.atherosclerosis.2013.08.019","article-title":"Effect of statin treatment on coronary plaque progression - a serial coronary CT angiography study","volume":"231","author":"Zeb","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.hlc.2016.12.005_bib0330","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.amjcard.2015.10.021","article-title":"A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk","volume":"117","author":"Kiyosue","year":"2015","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.hlc.2016.12.005_bib0335","unstructured":"Stroes ESG, Guyton J, Farnier M, Lepor N, Civeira F, Gaudet D, et al. Efficacy and safety of different dosing regimens of Alirocumab versus placebo in patients with hypercholesterolaemia not treated using statins: The ODYSSEY Choice I and II Studies. Paper presented at: American College of Cardiology 64th Annual Scientific Sessions and Expo 2015; March 14, 2015; San Diego, CA."}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950617300240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950617300240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T22:17:05Z","timestamp":1568758625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950617300240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1443950617300240"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2016.12.005","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 Monoclonal Antibodies in 2016: Current Status and Future Challenges","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2016.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}